Cargando…

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma

Inducible genetically defined mouse models of cancer uniquely facilitate the investigation of early events in cancer progression, however, there are valid concerns about the ability of such models to faithfully recapitulate human disease. We developed an inducible mouse model of progressive lung ade...

Descripción completa

Detalles Bibliográficos
Autores principales: Neidler, Sarah, Kruspig, Björn, Hewit, Kay, Monteverde, Tiziana, Gyuraszova, Katarina, Braun, Attila, Clark, William, James, Daniel, Hedley, Ann, Nieswandt, Bernhard, Shanks, Emma, Dick, Craig, Murphy, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562816/
https://www.ncbi.nlm.nih.gov/pubmed/31032816
http://dx.doi.org/10.3390/cancers11050600
_version_ 1783426409848373248
author Neidler, Sarah
Kruspig, Björn
Hewit, Kay
Monteverde, Tiziana
Gyuraszova, Katarina
Braun, Attila
Clark, William
James, Daniel
Hedley, Ann
Nieswandt, Bernhard
Shanks, Emma
Dick, Craig
Murphy, Daniel J.
author_facet Neidler, Sarah
Kruspig, Björn
Hewit, Kay
Monteverde, Tiziana
Gyuraszova, Katarina
Braun, Attila
Clark, William
James, Daniel
Hedley, Ann
Nieswandt, Bernhard
Shanks, Emma
Dick, Craig
Murphy, Daniel J.
author_sort Neidler, Sarah
collection PubMed
description Inducible genetically defined mouse models of cancer uniquely facilitate the investigation of early events in cancer progression, however, there are valid concerns about the ability of such models to faithfully recapitulate human disease. We developed an inducible mouse model of progressive lung adenocarcinoma (LuAd) that combines sporadic activation of oncogenic KRas(G12D) with modest overexpression of c-MYC (KM model). Histological examination revealed a highly reproducible spontaneous transition from low-grade adenocarcinoma to locally invasive adenocarcinoma within 6 weeks of oncogene activation. Laser-capture microdissection coupled with RNA-SEQ (ribonucleic acid sequencing) was employed to determine transcriptional changes associated with tumour progression. Upregulated genes were triaged for relevance to human LuAd using datasets from Oncomine and cBioportal. Selected genes were validated by RNAi screening in human lung cancer cell lines and examined for association with lung cancer patient overall survival using KMplot.com. Depletion of progression-associated genes resulted in pronounced viability and/or cell migration defects in human lung cancer cells. Progression-associated genes moreover exhibited strong associations with overall survival, specifically in human lung adenocarcinoma, but not in squamous cell carcinoma. The KM mouse model faithfully recapitulates key molecular events in human adenocarcinoma of the lung and is a useful tool for mechanistic interrogation of KRAS-driven LuAd progression.
format Online
Article
Text
id pubmed-6562816
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65628162019-06-17 Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma Neidler, Sarah Kruspig, Björn Hewit, Kay Monteverde, Tiziana Gyuraszova, Katarina Braun, Attila Clark, William James, Daniel Hedley, Ann Nieswandt, Bernhard Shanks, Emma Dick, Craig Murphy, Daniel J. Cancers (Basel) Article Inducible genetically defined mouse models of cancer uniquely facilitate the investigation of early events in cancer progression, however, there are valid concerns about the ability of such models to faithfully recapitulate human disease. We developed an inducible mouse model of progressive lung adenocarcinoma (LuAd) that combines sporadic activation of oncogenic KRas(G12D) with modest overexpression of c-MYC (KM model). Histological examination revealed a highly reproducible spontaneous transition from low-grade adenocarcinoma to locally invasive adenocarcinoma within 6 weeks of oncogene activation. Laser-capture microdissection coupled with RNA-SEQ (ribonucleic acid sequencing) was employed to determine transcriptional changes associated with tumour progression. Upregulated genes were triaged for relevance to human LuAd using datasets from Oncomine and cBioportal. Selected genes were validated by RNAi screening in human lung cancer cell lines and examined for association with lung cancer patient overall survival using KMplot.com. Depletion of progression-associated genes resulted in pronounced viability and/or cell migration defects in human lung cancer cells. Progression-associated genes moreover exhibited strong associations with overall survival, specifically in human lung adenocarcinoma, but not in squamous cell carcinoma. The KM mouse model faithfully recapitulates key molecular events in human adenocarcinoma of the lung and is a useful tool for mechanistic interrogation of KRAS-driven LuAd progression. MDPI 2019-04-29 /pmc/articles/PMC6562816/ /pubmed/31032816 http://dx.doi.org/10.3390/cancers11050600 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Neidler, Sarah
Kruspig, Björn
Hewit, Kay
Monteverde, Tiziana
Gyuraszova, Katarina
Braun, Attila
Clark, William
James, Daniel
Hedley, Ann
Nieswandt, Bernhard
Shanks, Emma
Dick, Craig
Murphy, Daniel J.
Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
title Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
title_full Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
title_fullStr Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
title_full_unstemmed Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
title_short Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
title_sort identification of a clinically relevant signature for early progression in kras-driven lung adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562816/
https://www.ncbi.nlm.nih.gov/pubmed/31032816
http://dx.doi.org/10.3390/cancers11050600
work_keys_str_mv AT neidlersarah identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT kruspigbjorn identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT hewitkay identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT monteverdetiziana identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT gyuraszovakatarina identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT braunattila identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT clarkwilliam identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT jamesdaniel identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT hedleyann identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT nieswandtbernhard identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT shanksemma identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT dickcraig identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma
AT murphydanielj identificationofaclinicallyrelevantsignatureforearlyprogressioninkrasdrivenlungadenocarcinoma